Science Foundation Arizona (SFAz) encourages Community College Hispanic Serving Institutions (HSIs) that meet eligibility requirements to apply for Cohort 3 of the KickStarter Program with support by National Science Foundation (NSF HRD# 1450061).
It is well-recognized that patients receiving carboplatin as second-line treatment of ovarian. cancer have at least a modest risk for experiencing hypersensitivity reactions.1 The onset of. reactions is unpredictable and they could occur immediately upon initiation of the drug infusion. or may not be seen until one half or more of the infusion has been administered to the patient. On the other hand, the onset of the reactions has also been reported in patients receiving more. than six cumulative courses. The symptoms associated with the reactions range from a minor. rash to diffuse erythroderma, pruritis, severe anxiety, dyspnea, tachycardia, hypotension, and in. severe cases, death.
Hypersensitivity or anaphylactic reactions during chemotherapy. Key facts: â¢ Can occur with giving the initial dose of a drug or during subsequent infusion of it. â¢ Can occur at the beginning, middle, or end of the infusion. â¢ Hypersensitivity risk varies according to drug given. What to look for: â¢ Specific signs and symptoms vary with the severity of the reaction. â¢ Severe hypersensitivity and anaphylactic reactions are considered emergencies. and require immediate treatment.